Business Update18 Aug 2026, 04:11 pm
Shilpa Medicare Recalls 27,923 Vials of Chemotherapy Drug in US
AI Summary
Shilpa Medicare Ltd has voluntarily recalled over 27,923 vials of its Pemetrexed Injection in the United States due to atypical discoloration. The recall, initiated on July 29, 2026, covers four batches of the chemotherapy drug. The US FDA has classified this as a Class II recall. The company stated that no adverse events have been reported and does not anticipate any material impact on its financial position or operations. This disclosure is made in response to a news report published on August 17, 2026.
Key Highlights
- Voluntary recall of 27,923 vials of Pemetrexed Injection in the US.
- Recall due to atypical green discoloration, classified as Class II by US FDA.
- No adverse events reported; no material financial or operational impact expected.
- Disclosure made in response to a news item in The Economic Times.
Price Impact
More from SHILPAMED